Guardant Health (GH) investors have a new number to think about this week.  Bernstein SocGen Group raised its price target on the cancer-screening company's stock to $200 a share, up from $175.

For Q2, according to Seeking Alpha, analysts are expecting normalized EPS of $1.28, GAAP EPS of $0.97, and $12.52bn of ...

They told me it was effective, and I knew mailing a Cologuard box back would be pretty dang easy.” Cologuard — a simple way ...

The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...

The American Cancer Society released updated guidelines for colorectal cancer screening, adding options for a blood-based ...

Unfortunately, Grail had bad news for investors in February when it released top-line results from the NHS and outlined that it had missed its primary endpoint of demonstrating "statistically ...

Following the close, the company gained a broad portfolio and differentiated pipeline aimed at early detection of cancer and personalized treatment decisions. This includes Cologuard, a non-invasive ...

(CNN) — The American Cancer Society is adding some new testing options to its screening guideline for colorectal cancers – and for the first time, that includes a blood test. Colonoscopies are still ...

On May 27, the American Cancer Society published updated screening guidelines for colorectal cancer, officially adding Guardant Health’s FDA-approved Shield blood test to its list of approved ...

For the first time, a blood test has been added to the list of the American Cancer Society’s recommended screenings for colorectal cancer. It’s not meant to replace colonoscopies, aiming instead at ...